New Clinically Tested Approach for Families Concerned with ADHD
GREENVILLE, S.C. - (BUSINESS WIRE) - VAYA Pharma (a division of Enzymotec LTD) announced the availability of Vayarin in pharmacies throughout North Carolina, South Carolina and Texas for children suffering with Attention-Deficit / Hyperactivity Disorder (ADHD).
Vayarin(TM) Now Available (Photo: Business Wire)
Vayarin, a once-daily formulation of Phosphatidylserine - Omega 3 compound EPA enriched, is prescription-only and offers a new approach to help manage ADHD symptoms in children. Vayarin has been clinically shown to safely reduce disruptive ADHD symptoms including, hyperactivity, inattention, restlessness and impulsivity both at home and at school. Additionally, Vayarin was clinically shown to improve the quality of life for the families of the ADHD children. Vayarin is a Medical Food regulated by the FDA under the Orphan Drug Act and is intended for use under physician supervision with consideration for the distinct nutritional requirements of children suffering with ADHD. Vayarin's recommended dose is 2 capsules once daily or as directed by a physician. It's specially formulated; easy to swallow hard shell capsule can also be opened and sprinkled on food. Vayarin is not a stimulant or a controlled substance and has no potential for abuse or dependence. Yoel Asseraf, CEO of VAYA Pharma division, stated, "Recently conducted market research reveals an unmet need for parents to have an alternative safe approach to help manage ADHD symptoms as it was shown that approximately 50% of the children diagnosed with ADHD are concerned to begin current treatment options. Vayarin specifically addresses this need, as its compounds are familiar to the human body and therefore has a improved safety profile. Vayarin was launched in Israel last year by Teva Pharmaceuticals and the feedback from physicians and parents has been very positive."
Vayarin Clinical Data
Related Business Wire News